Effects of recombinant human erythropoietin in normal humans
- 14 March 2011
- journal article
- review article
- Published by Wiley in The Journal of Physiology
- Vol. 589 (6) , 1265-1271
Abstract
This review describes some of the physiological effects of recombinant human erythropoietin (EPO) in healthy humans. At the blood level EPO increases the arterial O2 content not only by increasing red blood cell volume, but also by an equally important decrease in plasma volume. Well before that, EPO causes a prompt decrease in plasma levels of renin and aldosterone. Renal clearance studies suggest that EPO decreases renal proximal tubular reabsorption rate leading to activation of the tubuloglomerular feedback mechanism and a fall in glomerular filtration rate. Thus, treatment with EPO may result in suppression of endogenous EPO production through a decrease in intrarenal oxygen consumption. EPO elevates the arterial blood pressure even in healthy subjects. The receptor for EPO is present in many tissues. However, the functional effects of EPO in the skeletal muscle seem limited, and although it has been speculated that non‐erythropoietic effects of EPO (angiogenesis, shift in muscle fibre types, cognitive effects) may be responsible for the increase in exercise performance, this has not been confirmed. EPO‐induced haemodynamic effects call for careful monitoring during the administration period. The metabolic, hormonal and renal effects of EPO do not seem to range beyond physiologically acceptable limits and are reversible. Taken together, EPO seems safe to use for experimental purposes in healthy volunteers.Keywords
This publication has 52 references indexed in Scilit:
- Erythropoietin down‐regulates proximal renal tubular reabsorption and causes a fall in glomerular filtration rate in humansThe Journal of Physiology, 2011
- Recombinant Human Erythropoietin in the Treatment of Acute Ischemic StrokeStroke, 2009
- Erythropoietin Over-Expression Protects against Diet-Induced Obesity in Mice through Increased Fat Oxidation in MusclesPLOS ONE, 2009
- The Ergogenic Effect of Recombinant Human Erythropoietin on V̇O2max Depends on the Severity of Arterial HypoxemiaPLOS ONE, 2008
- Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volumeThe Journal of Physiology, 2006
- Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietinMolecular Psychiatry, 2006
- Effects of recombinant human erythropoietin injections on physical self in endurance athletesJournal of Sports Sciences, 2006
- The Role of Leptin in Human PhysiologyNew England Journal of Medicine, 1999
- Early and Late Effects of Erythropoietin on Glucose Metabolism in Maintenance Hemodialysis PatientsAmerican Journal of Nephrology, 1996
- Direct vasopressor effect of recombinant human erythropoietin on renal resistance vesselsKidney International, 1991